clinical trial data

Abstract modern white spiral clock dial with roman and arabic numerals
Biotech

Lilly links lepodisiran to durably lower lipoprotein in phase 2

Lilly saw sustained reductions for nearly 1.5 years, bolstering its argument that the siRNA candidate has an edge over rivals from Amgen and Novartis.
Nick Paul Taylor Mar 31, 2025 4:24am
Sketch of lungs

BioNTech posts survival data behind bispecific's phase 3 push

Mar 28, 2025 8:00am
dart board miss failure

Equillium misses primary, key secondaries, plans approval filing

Mar 27, 2025 9:52am
Candle in clear glass window with street in background

Candel's cancer survival data light path ahead in subpopulation

Mar 27, 2025 9:48am
relay

Immunovant posts phase 3 autoimmune win but won't seek approval

Mar 19, 2025 9:15am
positive negative up down good bad mixed

Incyte posts phase 3 skin condition wins but details disappoint

Mar 17, 2025 8:12am